Previous 10 | Next 10 |
Brickell Biotech, Inc. (BBI) Q4 2021 Earnings Conference Call March 15, 2022 08:30 AM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Andrew Sklawer - Co-Founder & Chief Operating Officer Albert Marchio II - Chief Financial Officer Monic...
The following slide deck was published by Brickell Biotech, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Brickell Biotech, Inc. 2021 Q4 - Results - Earnings Call Presentation
Brickell Biotech press release (NASDAQ:BBI): Q4 GAAP EPS of -$0.06 beats by $0.03. Revenue of $0.1M (+233.3% Y/Y) misses by $0.05M. The company reported cash and cash equivalents of $26.9M and expects it to support operations beyond the receipt of Phase 1 SAD and MAD topline results for ...
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform On track to initiate P...
Brickell Biotech (NASDAQ:BBI) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is -$0.09 (+40.0% Y/Y) and the consensus Revenue Estimate is $0.15M (-44.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward rev...
ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
BOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutic...
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutic...
Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism Agreement enhances Brickell’s pipeline in immunology and inflammation and leverages its drug development ca...
3 High Volume Penny Stocks For Your January Watchlist While trading penny stocks and blue chips has gotten off to a rough start this week, many investors are optimistic about the future. With the Dow Jones Industrial Average down by more than 500 points and the S&P 500 down by aroun...
News, Short Squeeze, Breakout and More Instantly...
Brickell Biotech Inc. Company Name:
BBI Stock Symbol:
NYSE Market:
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early precl...
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoi...